1. Japan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Nihon Kohden Corporation

Nihon Kohden Corporation

1,637.50
JPY
-15.00
(-0.91%)
232.76BMarket Cap
Nov 10Next Earn
Nihon Kohden Corporation
TSE:6849
(Tokyo Stock Exchange)

Recent

price

1,637.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
645.19
686.96
754.24
871.8
915.12
945.3
970.64
1,017.6
1,049.83
1,086.3
1,172.59
1,210.1
1,227.28
1,319.74
1,357.21
1,445.78
- -
Revenue per Share
37.4
43.37
52.08
70.26
63.41
60.06
53.4
53.46
65.71
57.86
107.1
138.25
101.64
101.22
84.88
89.25
- -
Basic EPS, GAAP
22.54
29.85
59.87
27.8
46.45
18.96
26.56
43.96
38.57
33.03
62
134.3
-63.97
64.33
39.6
81.16
- -
Free Cash Flow per Basic Share
9.78
11.5
11.24
14.96
18.79
17.29
17.49
17.5
17.51
17.5
17.49
28.56
34.06
35.48
30.71
32.18
- -
Dividend per Share
354.29
386.21
433.67
503.34
564.77
570.11
606.4
642.06
681.61
715
815.92
926.17
996.13
1,079.18
1,101.1
1,123.46
- -
Book Value per Share
331.13
366.18
396.82
465.48
526.16
533.97
573.73
612.24
654.82
690.64
802.25
904.05
971.05
1,050.27
931.51
953.29
- -
Tangible Book Value per Share
176
176
176
176
176
175
171
171
170
170
170
170
168
168
166
163
162
Basic Weighted Avg Shares
113,380
120,718
132,538
153,194
160,803
165,522
166,285
174,249
178,799
185,007
199,727
205,129
206,603
221,986
225,424
235,099
- -
Sales/Revenue/Turnover
9.35
9.96
10.17
11.45
9.9
9.93
8.17
8.33
8.41
8.38
13.57
15.11
10.22
8.83
9.19
7.97
- -
Operating Margin (%)
2,746
2,900
2,909
3,240
3,605
3,624
3,564
3,486
3,692
3,745
4,543
3,490
3,791
3,853
4,190
5,821
- -
Depreciation Expense
6,573
7,621
9,151
12,346
11,142
10,516
9,149
9,154
11,191
9,854
18,243
23,435
17,110
17,026
14,098
14,513
- -
Net Income, GAAP
36.05
37.32
36.96
34.98
36.02
33.84
33.95
34.39
27.88
29.51
32.84
31.6
30.77
42.02
34.64
26.9
- -
Effective Tax Rate (%)
5.8
6.31
6.9
8.06
6.93
6.35
5.5
5.25
6.26
5.33
9.13
11.42
8.28
7.67
6.25
6.17
- -
Profit Margin (%)
45,693
52,028
56,153
65,267
72,735
70,028
74,229
76,086
83,865
88,701
105,532
121,071
125,932
134,432
110,789
128,380
- -
Working Capital
48
21
28
31
30
29
16
17
17
42
43
24
17
39
38
22,527
- -
LT Debt
62,294
67,910
76,254
88,508
99,301
97,669
103,885
109,352
116,086
121,773
138,983
156,378
167,602
181,080
181,292
179,822
- -
Total Equity
10.32
11.02
11.15
13.02
10.38
10.68
8.64
8.71
9.35
8.93
13.39
13.69
8.76
6.34
6.79
6.56
- -
Return on Invested Capital (%)
10.7
11.52
12.51
14.76
11.75
10.56
9.03
8.56
9.89
8.26
13.95
15.83
10.54
9.74
7.29
7.13
- -
Return on Capital (%)
10.94
11.71
12.7
15
11.87
10.68
9.08
8.59
9.93
8.29
13.99
15.87
10.56
9.77
7.82
8.08
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
25,669
2,676
- -
LT Borrowings
- -
22,388
- -
LT Finance Leases
- -
139
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
163
160
160
Market Capitalization
275,735
232,760
228,441

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
173,324
177,808
- -
Cash, Cash Equivalents & STI
49,841
46,695
- -
Accounts Receivable, Net
58,651
65,973
- -
Inventories
60,076
55,990
- -
Total Current Liabilities
68,369
49,428
- -
Payables & Accruals
- -
- -
- -
ST Debt
25,669
2,676
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.39%
5.41%
-0.81%
Free Cash Flow
-0.77%
-34.16%
100.65%
Net Income, GAAP
6.92%
-2.66%
2.94%
Sales/Revenue/Turnover
3.6%
3.34%
4.29%
Total Cash Common Dividend
7.15%
14.62%
2.61%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
225,424
2026
- -
- -
- -
- -
235,099
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
84.88
2026
- -
- -
- -
- -
89.25
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
30.71
2026
- -
- -
- -
- -
32.18
2027
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Nihon Kohden Corporation manufactures, develops, sells, maintains, and provides consultation for medical electronic equipment and related systems worldwide. Founded in 1951 and headquartered in Tokyo, Japan, the company operates in over 120 countries across Japan, the Americas, Europe, Asia, and other regions, serving hospitals, clinics, and research facilities with products focused on physiological measurement, patient monitoring, treatment, IT solutions, and laboratory equipment. Its core offerings include electroencephalographs, electrocardiographs, evoked potential/EMG measuring instruments, and polygraphs for cath-labs; patient monitoring systems for emergency rooms, operating rooms, intensive care units, general wards, transport, remote ICU, central nursing, and ambulatory telemetry; defibrillators and automated external defibrillators; imported and in-house ventilators, pacemakers, and ICDs; clinical information systems and diagnostic IT platforms for laboratories, operating rooms, and wards; blood cell counters with reagents; and clinical chemistry analyzers measuring C-reactive protein and HbA1c. In late 2024, Nihon Kohden acquired a 71.4% stake in NeuroAdvanced Corp., parent of Ad-Tech Medical Instrument Corporation, for approximately ¥16 billion to expand its neurology electrode portfolio for epilepsy care, forming a joint venture with seller ArchiMed; in 2025, it agreed to acquire the remaining 28.6% stake for ¥7.4 billion, achieving full ownership. The company launched Nihon Kohden Payment Solutions in May 2025, offering flexible financing terms from 12 to 60 months for healthcare providers to acquire monitoring and diagnostic equipment. It is constructing a new plant in Tsurugashima City, with operations planned to start in 2026 following PLM/MES system implementation completed in October 2025, as part of investments totaling around ¥11 billion.

Company News

Company News APIChatGPT

  • defenseworld.net

    Analyzing Beta Bionics (NASDAQ:BBNX) and Nihon Kohden (OTCMKTS:NHNKY)

  • businesswire.com

    Nihon Kohden Expands Executive Leadership to Support Continued Growth and Customer Experience

  • businesswire.com

    Nihon Kohden Upgrades NKV-550, Now First Ventilator Combining Non-Invasive Muscle Pressure Monitoring, AVM and Adjustable AdaptiveSync™ Manufactured in the U.S.

  • defenseworld.net

    Nihon Kohden (OTCMKTS:NHNKY) versus Nuwellis (NASDAQ:NUWE) Head to Head Contrast

  • defenseworld.net

    Nihon Kohden (OTCMKTS:NHNKY) Shares Gap Up – What’s Next?

  • businesswire.com

    Nihon Kohden Brings Advanced EEG Technology Built on 70 Years of Innovation to Booth #725 at the American Epilepsy Society 2025 Annual Meeting